Regulatory Toxicology and Pharmacology xxx (2014) xxx-xxx

Contents lists available at ScienceDirect



5 6

12 13

3 0

Regulatory Toxicology and Pharmacology

31

32

33 34

35

36

37

38

39

40

41

42

43

44 45

46 47

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

## **Regulatory Toxicology and Pharmacology**

journal homepage: www.elsevier.com/locate/yrtph

### Evaluating the performance of integrated approaches for hazard 3 identification of skin sensitizing chemicals

7 Q1 Jochem W. van der Veen<sup>b,a</sup>, Emiel Rorije<sup>b</sup>, Roger Emter<sup>c</sup>, Andreas Natsch<sup>c</sup>, Henk van Loveren<sup>b,a</sup>, Ianine Ezendam<sup>b,\*</sup> 8

۵ <sup>a</sup> Department of Toxicogenomics, Maastricht University, PO Box 616, NL-6200 MD Maastricht, The Netherlands 10

<sup>b</sup> National Institute for Public Health and the Environment (RIVM), PO Box 1, NL-3720BA Bilthoven, The Netherlands

11 <sup>c</sup> Givaudan Schweiz AG, Ueberlandstrasse 138, CH-8600 Dübendorf, Switzerland

#### ARTICLE INFO

16 Article history 17 Received 13 January 2014 18 Available online xxxx

19 Keywords. 20 Skin sensitization 21 Integrated testing strategy 22 Keratinocytes 23 Allergic contact dermatitis 24 Animal-free testing 25 LLNA 26 QSAR 27 DPRA 28 Adverse outcome pathway

#### ABSTRACT

The currently available animal-free methods for the detection of skin sensitizing potential of chemicals seem promising. However, no single method is able to comprehensively represent the complexity of the processes involved in skin sensitization. To ensure a mechanistic basis and cover the complexity, multiple methods should be integrated into a testing strategy, in accordance with the adverse outcome pathway that describes all key events in skin sensitization. Although current majority voting testing strategies have proven effective, the performance of individual methods is not taken into account. To that end, we designed a tiered strategy based on complementary characteristics of the included methods, and compared it to a majority voting approach. This tiered testing strategy was able to correctly identify all 41 chemicals tested. In terms of total number of experiments required, the tiered testing strategy requires less experiments compared to the majority voting approach. On the other hand, this tiered strategy is more complex due the number of different alternative methods required, and predicted costs are similar for both strategies. Both the tiered and majority voting strategies provide a mechanistic basis for skin sensitization testing, but the strategy most suitable for regulatory decision-making remains to be determined.

© 2014 Published by Elsevier Inc.

#### 48 1. Introduction <u>4</u>9

Changes in EU legislations, such as the 7th amendment to the 50 cosmetics directive and the REACH regulation (EC, 2006, 2008), 51 have prompted the development of alternative methods that 52 assess skin sensitizing potential of chemicals (Adler et al., 2011; 53 Rovida et al., 2013; Vandebriel and van Loveren, 2010). Although 54 several of these alternatives seem promising (Zuang et al., 2013), 55 it is unlikely that a single method can capture the complexity of 56 the processes involved in skin sensitization. It is therefore foreseen 57 58 that multiple alternative methods need to be integrated into a test-59 ing strategy for reliable classification of chemicals. The Organiza-60 tion for Economic Co-operation and Development (OECD) has proposed an adverse outcome pathway (AOP) that describes the 61 molecular initiating event and key events that lead to allergic 62 63 contact dermatitis (ACD) (OECD, 2012). This AOP can guide the integration of methods that each represent a different key event 64 65 in the development of ACD.

bioavailability of the chemical and the cellular metabolism that either activates or inactivates a chemical. The initiating event is the basis for methods that predict sensitizing potential of chemicals through the binding capability of chemicals, such as the ECVAM-validated direct peptide reactivity assay (DPRA) (Gerberick et al., 2004; EC-JRC, 2013a) or quantitative structureactivity relationships (QSARs). Subsequently, the epithelial cells respond to the haptens and hapten-protein complexes, mainly through the production and release of cytokines and stress markers by keratinocytes (KC). This includes interleukin IL-18, which can be used to predict the sensitizing potential of chemicals in epithelial cell lines and 3D-skin models (Gibbs et al., 2013; McKim et al., 2010; Corsini et al., 2009; Van Och et al., 2005). In addition, cellular stress caused by chemicals activates cytoprotective responses such as the Nrf2-Keap1 pathway, which serves as the basis of several reporter assays, such as the KeratinoSens assay for which the ECVAM-validation report is expected soon (EC-JRC, 2013b; Emter et al., 2010). Methods that assess multiple stress related cellular mechanisms are available, such as a gene signature that includes

The binding of a chemical to proteins is considered the molec-

ular initiating event of skin sensitization and is influenced by

\* Corresponding author. E-mail address: Janine.ezendam@rivm.nl (J. Ezendam).

http://dx.doi.org/10.1016/j.yrtph.2014.04.018 0273-2300/© 2014 Published by Elsevier Inc.

Please cite this article in press as: van der Veen, J.W., et al. Evaluating the performance of integrated approaches for hazard identification of skin sensitizing chemicals. Regul. Toxicol. Pharmacol. (2014), http://dx.doi.org/10.1016/j.yrtph.2014.04.018

143

144

145

2

87

88

J.W. van der Veen et al./Regulatory Toxicology and Pharmacology xxx (2014) xxx-xxx

biomarker genes with roles in oxidative stress, immune response and gene regulation (van der Veen et al., 2013).

89 The next key event outlines the activation of dendritic cells 90 (DC), which is influenced by both the chemical and the mediators 91 released by keratinocytes. Activation leads to up-regulation of 92 co-stimulatory molecules, such as CD86. In the h-Clat and MUSST 93 methods this is indicative of the skin sensitizing potential of chem-94 icals (Nukada et al., 2011). The h-Clat has been validated by EURL 95 ECVAM and results are expected in 2014. Upon activation, DCs migrate out of the skin towards the closest lymph node and pres-96 97 ent a peptide-hapten conjugate on the MHC-class II protein, here 98 the T-cells can recognize the haptenated peptide and start their clonal expansion. This event is measured in the LLNA, but currently 99 no routine in vitro assay is available to assess this step in the AOP 100 101 (Martin et al., 2010; Adler et al., 2011; OECD, 2012).

102 These animal-free classification methods can be combined in a 103 testing strategy in which molecular initiating and key events of the 104 AOP are captured. Recently, a majority voting approach was proposed in which results from the DPRA, KeratinoSens and MUSST 105 methods are used to classify a chemical according to the most 106 107 prevalent prediction (Natsch et al., 2013; Bauch et al., 2012). In this 108 study, we compared this majority voting strategy to a tiered testing strategy that is based on the predictive performance of 109 the included methods. 110

#### 111 2. Materials and methods

#### 112 2.1. Chemicals

113 The sensitizing and non-sensitizing chemicals used in this study 114 are shown in Table 1. The sensitizing compounds were selected 115 based on human evidence and to reflect various potency classes. 116 In addition, chemicals that have proven either false-positive or 117 false-negative in the LLNA were included (Gerberick et al., 2005). 118 All compounds were obtained from Sigma-Aldrich (Zwijndrecht, 119 The Netherlands), except for 2-Mercaptobenzothiazole, which 120 was obtained from Merck (Schiphol-Rijk, The Netherlands). Chem-121 icals were dissolved in either absolute ethanol or dimethylsulfoxide (DMSO) and then added to the cells to a final solvent 122 123 concentration of 1%.

#### 124 2.2. Methods reflecting protein reactivity

The protein reactivity of chemicals was assessed using the individually effective methods of *in chemico* peptide reactivity methods and *in silico* QSAR methods.

#### 128 2.3. Peptide reactivity

129 A literature search was performed to establish for which of the 130 chemicals peptide reactivity has been assessed in chemico (Natsch 131 et al., 2013; Bauch et al., 2012; Gerberick et al., 2007). The peptide reactivity of the 4 chemicals (tBHQ, TIBP, MA and HEG) that were 132 133 not described in literature was evaluated using the DPRA (Gerberick et al., 2007). In short, the chemical was added to a syn-134 135 thetic peptide containing either a cysteine or a lysine. The mixture 136 was then analyzed with HPLC using UV detection. After 24 h the 137 mixture was analyzed again, a sensitizing chemical is designated by a significant decrease in the peak related to the unmodified 138 139 peptide.

#### 140 2.4. QSAR predictions for skin sensitization

141 In order to evaluate the predictive value of skin sensitization 142 QSARs for our chemical set, the non-commercial QSAR models of MultiCASE, CAESAR, DEREK and the OECD QSAR toolbox were applied to all chemicals to generate prediction of skin sensitization potential, these models are briefly described here.

MultiCASE (Klopman et al., 2005) generates QSAR models based 146 on substructure fragments linked to biological activity. A Multi-147 CASE implementation for skin sensitization from the Danish EPA 148 (DTU, 2013) is used here. In the present study, only the positive 149 and negative predictions within the applicability domain were 150 taken into account. The CAESAR model (Chaudhry et al., 2010) uses 151 atom centered fragments as descriptors in a multivariate statistical 152 model. The model gives a prediction of active or inactive (as skin 153 sensitizer), together with applicability domain information. Again, 154 only predictions of active or inactive within the applicability 155 domain are taken into account. The DEREK knowledgebase 156 (Lhasa, 2013) is a collection of structural alerts linked to skin sen-157 sitization. The model only identifies skin sensitizers and is not 158 meant to identify non-sensitizers. Despite this limitation, we have 159 interpreted the absence of any structural alert as a prediction of 160 non-sensitization. DEREK predictions of "certain", "probable" and 161 "plausible" were considered as positive predictions of skin sensiti-162 zation. Predictions of "improbable", "impossible" or "nothing to 163 report" were interpreted as a prediction of non-sensitization. 164 Equivocal predictions were not taken into account. In the OECD 165 QSAR Toolbox software (OECD, 2013) an implementation of a set 166 of protein binding reactivity alerts from Enoch et al. (2008) is pres-167 ent, as the "Protein binding" profile. These alerts are considered 168 indicative of reactivity towards proteins, and subsequently any 169 substance that has an alert in this profile is considered a skin sen-170 sitizer for this study. Absence of any of the alerts in this profile was 171 taken as a prediction of non-sensitization. 172

2.5. Independent Bayesian approach to evaluate a battery of QSAR predictions

Instead of characterizing the individual predictivity of the QSAR models for our dataset, a classification of the four QSAR models combined (QSAR-battery) was generated, based on Bayesian statistics. A detailed description of the methodology, applied to skin sensitization, can be found in Rorije et al. (2013). In addition, the applicability domain information provided by the individual QSAR methods is taken into account. Furthermore, a newer version of the DEREK knowledge base and an entirely new model (CAESAR) are introduced here. The specificity and sensitivity of each model used in our Bayesian analysis, taking into account the applicability domain information in the case of MultiCASE and CAESAR, are based on the analysis of a large number of chemicals in comparison with the LLNA (Table 2).

Threshold values used to determine a reliable prediction from the battery of QSARs are applied as proposed in Rorije et al. (2013). These values are >80% or >90% probability for a positive or a negative conclusion respectively. This is based on the reliability with which the GPMT test predicts the LLNA outcome (or vice versa) in the official LLNA validation study (NICEATM-ICCVAM, 1999). If there are insufficient or conflicting results from the battery of QSAR models, these thresholds will not be reached and substances are considered equivocal.

#### 2.6. Methods reflecting epithelial response

To assess which *in vitro* approach would be most effective in a 198 tiered strategy, the expression of biomarker genes, activation of 199 the Nrf2 transcription factor, and production of interleukin 18 were evaluated. 201

197

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

Please cite this article in press as: van der Veen, J.W., et al. Evaluating the performance of integrated approaches for hazard identification of skin sensitizing chemicals. Regul. Toxicol. Pharmacol. (2014), http://dx.doi.org/10.1016/j.yrtph.2014.04.018

Download English Version:

# https://daneshyari.com/en/article/5857038

Download Persian Version:

https://daneshyari.com/article/5857038

Daneshyari.com